Health Economics›Non-small cell lung cancer›Advanced or metastatic disease EGFR p.T790M mutation

Advanced or metastatic disease EGFR p.T790M mutation

Non-small cell lung cancer · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Osimertinib monotherapy Variant #01	EGFR	R 155 554	28d	16.6 mo	38.1 mo	2	R 311 108 PFS proxy	13
Docetaxel and Bevacizumab Variant #01	EGFR	R 32 908	21d	~8.2 mo	—	~2	~R 65 815 PFS proxy · indirect	4
Carboplatin and Pemetrexed Variant #01	EGFR	R 14 563	21d	5.6 mo	22.5 mo	3	R 43 688 PFS proxy	18
Cisplatin and Pemetrexed Variant #01	EGFR	R 13 666	21d	5.5 mo	22.5 mo	4	R 54 665 PFS proxy	20

4 of 4 regimens shown